Genprex | Investor Presentation Deck

Slide schematic 4/4

diagram 1/1 image 1/1 paragraph 1/1 title 1/1

Components 4

timeline logo paragraph headline

Tools 1

paragraph/paragraph: Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso. FDA Fast Track Designation. ~10-15 U.S. sites. ~119 patients. Phase 1 Dose Escalation: 12 patients. Phase 2a Expansi

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

timeline 90%

The slide uses a sequential flow diagram to represent clinical trial phases.

Find anything

The slide outlines a multi-phase clinical trial structure (Phase 1, 2a, 2b) and provides specific patient counts and interim analysis milestones.